Search Result

Results for "

ischemia-reperfusion injury model

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Akt (1) Angiotensin-converting Enzyme (ACE) (1) Annexin A (2) Apoptosis (2) Autophagy (1) Bacterial (1) Biochemical Assay Reagents (1) Calcium Channel (1) Dynamin (2) ERK (3) Ferroptosis (1) IKK (1) Insulin Receptor (1) Integrin (1) Interleukin Related (2) Keap1-Nrf2 (1) MAP3K (1) MEK (1) mTOR (1) Na+/H+ Exchanger (NHE) (2) NF-κB (4) NO Synthase (1) NOD-like Receptor (NLR) (1) P2Y Receptor (2) p38 MAPK (1) PKC (2) Protease Activated Receptor (PAR) (2) Pyroptosis (1) Ras (1) Reactive Oxygen Species (2) TNF Receptor (2) Tyrosinase (1) VEGFR (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (18) Infection (1) Inflammation/Immunology (17) Metabolic Disease (1) Neurological Disease (4)

By Targets:

Adenosine Receptor (1)

Akt (1)

Angiotensin-converting Enzyme (ACE) (1)

Annexin A (2)

Apoptosis (2)

Autophagy (1)

Bacterial (1)

Biochemical Assay Reagents (1)

Calcium Channel (1)

Dynamin (2)

ERK (3)

Ferroptosis (1)

IKK (1)

Insulin Receptor (1)

Integrin (1)

Interleukin Related (2)

Keap1-Nrf2 (1)

MAP3K (1)

MEK (1)

mTOR (1)

Na+/H+ Exchanger (NHE) (2)

NF-κB (4)

NO Synthase (1)

NOD-like Receptor (NLR) (1)

P2Y Receptor (2)

p38 MAPK (1)

PKC (2)

Protease Activated Receptor (PAR) (2)

Pyroptosis (1)

Ras (1)

Reactive Oxygen Species (2)

TNF Receptor (2)

Tyrosinase (1)

VEGFR (1)

By Research Areas:

Cancer (1)

Cardiovascular Disease (18)

Infection (1)

Inflammation/Immunology (17)

Metabolic Disease (1)

Neurological Disease (4)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117243

GSK329	MAP3K	Cardiovascular Disease
GSK329 is a potent and selective diarylurea inhibitor of the cardiac-specific kinase TNNI3K. GSK329 exhibits positive cardioprotective outcomes in the model of ischemia/reperfusion cardiac injury .

HY-106592A

U-74389G PNU74389G (meleate)	Reactive Oxygen Species	Cardiovascular Disease Others
U-74389G (PNU74389G meleate) is an antioxidant, can inhibit lipid peroxidation reactions. U-74389G can protect against ischemia-reperfusion injury and be widely used in animal models of ischemic injury and hypertension. U-74389G shows anti-inflammatory activity .

HY-119152

CMX-2043	Insulin Receptor Tyrosinase Akt	Others
CMX-2043 is a novel analogue of α-Lipoic Acid (HY-N0492). CMX-2043 is effective in antioxidant effect, activation of insulin receptor kinase, soluble tyrosine kinase, and Akt phosphorylation. CMX-2043 shows protection against ischemia-reperfusion injury (IRI) in rat model .

HY-121726

3HOI-BA-01	mTOR Autophagy	Cardiovascular Disease
3HOI-BA-01 is amTORinhibitor.3HOI-BA-01reduces infarct size and inducedautophagyin a murine myocardial ischemia/reperfusion injury model .

HY-170747

9-tert-Butyldoxycycline	Bacterial	Infection Inflammation/Immunology
9-tert-Butyldoxycycline exhibits immunomodulatory activity, alters the polarization states polymorphonuclear neutrophils, and ameliorates the inflammatory response in ischemia-reperfusion injury model. 9-tert-Butyldoxycycline is the ligand for ‘Tet-On’ switch system .

HY-161717

MRS5663	Adenosine Receptor	Cardiovascular Disease
MRS5663 (Compound 3a) is an A3AR agonist, with an EC₅₀ of 5.62 nM for β-arrestin2 recruitment assay. MRS5663 has a cytoprotective effect on skeletal muscle ischemia-reperfusion injury/claudication model .

HY-P3199

PKCβII Peptide Inhibitor I	PKC	Inflammation/Immunology
PKCβII Peptide Inhibitor I is a PKCβII inhibitor. PKCβII Peptide Inhibitor I shows cardioprotective effects in rat cardiac Ischemia/reperfusion injury model. PKCβII Peptide Inhibitor I also prevents vascular endothelial dysfunction .

HY-117356B

MRS2693 trisodium	P2Y Receptor NF-κB ERK	Cardiovascular Disease
MRS2693 trisodium is a selective P2Y6 agonist with an EC₅₀ value of 0.015 μM. MRS2693 trisodium can reduce the activation of NF-kappaB and activate the ERK1/2 pathway, and has a cytoprotective effect on mouse hindlimb skeletal muscle ischemia-reperfusion injury model .

HY-W783623

1,3-Didocosahexaenoyl glycerol DG(22:6/0:0/22:6); 1,3-Didocosahexaenoin	Biochemical Assay Reagents	Cardiovascular Disease
1,3-Didocosahexaenoyl glycerol (DG(22:6/0:0/22:6); 1,3-Didocosahexaenoin) is an ω-3 polyunsaturated fatty acid, which exhibits cardioprotective effects in rat myocardial ischemia/reperfusion (I/R) injury model through conjugation with Poly-l-glutamic acid (PGA) .

HY-161992

Nrf2 activator-11	Keap1-Nrf2 Apoptosis	Neurological Disease Inflammation/Immunology
Nrf2 activator-11 (compound M11) is a Nrf2 activator with blood-brain permeability. Nrf2 activator-11 has anti-oxidation, anti-inflammation, anti-ferroptosis and anti-apoptosis. Nrf2 activator-11 can be used to study cerebral  ischemia-reperfusion (CI/R) injury models .

HY-108467

GGsTop 3 Publications Verification Nahlsgen	Others	Cardiovascular Disease
GGsTop (Nahlsgen) is a potent, non-toxic, highly selective and irreversible γ-GGT inhibitor, with a K_i of 170 μM for Human GGT. GGsTop shows a pK_a of 9.71, also exhibits K_ons of 150 and 51 M ^-1 s ^-1 against E.coli GGT and human GGT, respectively. GGsTop protects hepatic ischemia-reperfusion injury in rat model .

HY-152086

DRP1i27	Dynamin	Cardiovascular Disease
DRP1i27 is a potent inhibitor of human Drp1 (dynamin-related protein 1). DRP1i27 binds to the GTPase site of Drp1, with hydrogen bonds to Gln34 and Asp218. DRP1i27 targets Drp1-mediated mitochondrial fission in cell line models and protects against simulated ischemia-reperfusion injury .

HY-152086A

DRP1i27 dihydrochloride	Dynamin	Cardiovascular Disease
DRP1i27 dihydrochloride is a potent inhibitor of human Drp1 (dynamin-related protein 1). DRP1i27 dihydrochloride binds to the GTPase site of Drp1, with hydrogen bonds to Gln34 and Asp218. DRP1i27 dihydrochloride targets Drp1-mediated mitochondrial fission in cell line models and protects against simulated ischemia-reperfusion injury .

HY-P1098

Ac2-26 4 Publications Verification	Annexin A NF-κB	Inflammation/Immunology
Ac2-26 is the N-terminal peptide of annexin 1, and has anti-inflammatory activity. Ac2-26 induces a decrease in IKKβ protein in lysosomes by chaperone-mediated autophagy (CMA). Ac2-26 ameliorates lung ischemia-reperfusion injury. Ac2-26 also inhibits airway inflammation and hyperresponsiveness in an asthma rat model .

HY-P1098A

Ac2-26 TFA 4 Publications Verification	Annexin A NF-κB	Inflammation/Immunology
Ac2-26 TFA is the N-terminal peptide of annexin 1, and has anti-inflammatory activity. Ac2-26 induces a decrease in IKKβ protein in lysosomes by chaperone-mediated autophagy (CMA). Ac2-26 ameliorates lung ischemia-reperfusion injury. Ac2-26 also inhibits airway inflammation and hyperresponsiveness in an asthma rat model .

HY-120485

Raxofelast IRFI-016	p38 MAPK ERK PKC	Cardiovascular Disease
Raxofelast (IRFI-016) is an antioxidant agent in various models of ischemia-reperfusion injury. Raxofelast has antiproliferative activity in H₂O₂-stimulated rat aortic smooth muscle cells. Raxofelast attenuates the activation of mitogen-activating protein kinase (MAPK), ERK kinase 1, 2 (MEK1,2) and protein kinase C (PKC) without affecting Ras expression .

HY-P5875

P4pal10	Protease Activated Receptor (PAR)	Cardiovascular Disease Inflammation/Immunology
P4pal10 is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 ameliorates the injury in mice myocardial ischemia/reperfusion (I/R) models .

HY-P1098B

Ac2-26 ammonium 4 Publications Verification	IKK	Inflammation/Immunology
Ac2-26 ammonium is the N-terminal peptide of annexin 1, and has anti-inflammatory activity. Ac2-26 ammonium induces a decrease in IKKβ protein in lysosomes by chaperone-mediated autophagy (CMA). Ac2-26 ammonium ameliorates lung ischemia-reperfusion injury. Ac2-26 ammonium also inhibits airway inflammation and hyperresponsiveness in an asthma rat model .

HY-A0113

Cilazaprilat Ro 31-3113	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Cilazaprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC₅₀=0.7 nM for the rat enzyme) and an active metabolite of Cilazapril (HY-A0043). It decreases creatine kinase release in primary neonatal rat cardiac myocytes in an in vitro model of ischemia-reperfusion injury induced by hypoxia and reoxygenation when used at a concentration of 10 μM.3 Intra-arterial administration of cilazaprilat (3 μg/kg per minute) increases coronary blood flow and fractional shortening in a dog model of coronary hypoperfusion-induced myocardial ischemia.

HY-138454

MEG hemisulfate Mercaptoethylguanidine hemisulfate	NO Synthase	Inflammation/Immunology
MEG (Mercaptoethylguanidine) hemisulfate is a potent and selective inhibitor of the inducible NO synthase (iNOS), with EC₅₀s of 11.5, 110, and 60 μM for iNOS, ecNOS, and bNOS respectively in tissue homogenates. MEG hemisulfate is also a potent scavenger of peroxynitrite and inhibits peroxynitrite-induced oxidative processes. MEG hemisulfate has a protective effect in many experimental models of inflammation, including ischemia/reperfusion injury, periodontitis, hemorrhagic shock, inflammatory bowel disease, and endotoxic and septic shock .

HY-117356A

MRS2693 ammonium	P2Y Receptor NF-κB ERK Apoptosis	Inflammation/Immunology
MRS2693 ammonium is the ammonium dalt form of MRS2693 (HY-117356). MRS2693 ammonium is a selective agonist for P2Y6 with an EC₅₀ of 0.015 μM. MRS2693 ammonium protects C2C12 skeletal muscle cells from TNFα-induced apoptosis. MRS2693 ammonium reduces the activation of NF-kB, activates the ERK1/2 pathway, and has a cytoprotective effect on mouse ischemia-reperfusion injury model [2].

HY-18071

BI-9627 2 Publications Verification	Na+/H+ Exchanger (NHE)	Cardiovascular Disease
BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC₅₀s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury .

HY-18071A

BI-9627 hydrochloride 2 Publications Verification	Na+/H+ Exchanger (NHE)	Cardiovascular Disease
BI-9627 hydrochloride is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC50s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 hydrochloride displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 hydrochloride shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury .

HY-169059

Ferroptosis-IN-12	Ferroptosis	Inflammation/Immunology
Ferroptosis-IN-12 (Cpd-A1) is a ferroptosis inhibitor. Ferroptosis-IN-12 exhibits effective ferroptosis inhibition in Erastin (HY-15763)-treated mouse tubular epithelial cells (mTECs) and improves kidney function, alleviates renal tubular damage, and reduces inflammation in a dose-dependent manner in acute kidney injury (AKI) mouse models induced by ischemia/reperfusion (I/R) or cecal ligation and puncture (CLP). Ferroptosis-IN-12 demonstrates good plasma stability and high distribution in kidney tissues in pharmacokinetic studies in mice. Ferroptosis-IN-12 holds promise for research in the field of acute kidney injury (AKI) .

HY-155517

INF200	NOD-like Receptor (NLR) Pyroptosis	Inflammation/Immunology
INF200 (compound 5) is a sulfonylurea-based inhibitor of NLRP3 and NLRP3-mediated pyroptosis. INF200 has beneficial cardiometabolic effects in rat model of high-fat diet (HFD)-induced metaflammation，and shows anti-inflammatory activity to (10 μM) decreases IL-1β release in human macrophages. INF200 improves glucose and lipid profiles，and attenuates systemic inflammation and biomarkers of cardiac dysfunction (particularly BNP). INF200 also improves myocardial damage-dependent ischemia/reperfusion injury (IRI) in hemodynamic evaluation .

HY-P99116

Faricimab RG7716	VEGFR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .

HY-P5875A

P4pal10 TFA	Protease Activated Receptor (PAR)	Cardiovascular Disease Inflammation/Immunology
P4pal10 TFA is the TFA salt form of P4pal10 (HY-P5875). P4pal10 TFA is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 TFA inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 TFA reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 TFA ameliorates the injury in rats myocardial ischemia/reperfusion (I/R) models .

HY-N0507

Rosavin	TNF Receptor Interleukin Related	Neurological Disease Inflammation/Immunology
Rosavin, an orally bioactive phenylpropanoid from Rhodiola rosea L. (RRL), is an adaptogen that enhances the body’s response to environmental stress. Rosavin significantly influences bone tissue metabolism by inhibiting osteoclastogenesis and promoting osteoblast differentiation, also impacts various diseases, demonstrating antidepressant, adaptogenic, and anxiolytic effects in mouse models. Additionally, Rosavin improves survival, reducing intestinal damage in irradiated rats and Ischemia-reperfusion(I/R)-induced cerebral injury in vivo by regulating inflammation and oxidative stress, making it a promising candidate for research in radiation-induced intestinal injury, I/R-induced cerebral injury and osteoporosis .

HY-125792

Nexinhib20	Reactive Oxygen Species Ras Integrin	Cardiovascular Disease Inflammation/Immunology
Nexinhib20 is an inhibitor that targets the interactions of Rab27a-JFC1 (IC₅₀: 2.6 μM) and Rac-1-GTP. Nexinhib20 can inhibit neutrophil exocytosis, adhesion, and β2 integrin activation, and has anti-inflammatory activity. Nexinhib20 can be used in the research of diseases such as systemic inflammation and myocardial ischemia-reperfusion injury .

HY-N0507R

Rosavin (Standard)	TNF Receptor Interleukin Related	Neurological Disease Inflammation/Immunology
Rosavin (Standard) is the analytical standard of Rosavin. This product is intended for research and analytical applications. Rosavin, an orally bioactive phenylpropanoid from Rhodiola rosea L. (RRL), is an adaptogen that enhances the body’s response to environmental stress. Rosavin significantly influences bone tissue metabolism by inhibiting osteoclastogenesis and promoting osteoblast differentiation, also impacts various diseases, demonstrating antidepressant, adaptogenic, and anxiolytic effects in mouse models. Additionally, Rosavin improves survival, reducing intestinal damage in irradiated rats and Ischemia-reperfusion(I/R)-induced cerebral injury in vivo by regulating inflammation and oxidative stress, making it a promising candidate for research in radiation-induced intestinal injury, I/R-induced cerebral injury and osteoporosis .

HY-B0023

Azelnidipine 2 Publications Verification CS 905	Calcium Channel MEK	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Azelnidipine (CS 905) is a dihydropyridine calcium channel blocker that is effective orally. Azelnidipine inhibits the intracellular calcium ion flow and lower blood pressure by selectively blocking L-type calcium channel on the membrane of vascular smooth muscle. Azelnidipine inhibits esophageal squamous cell carcinoma proliferation by targeting MEK1/2. Azelnidipine also has anti-inflammatory, antioxidant and neuroprotective effects .

Cat. No.	Product Name	Target	Research Area